Novo's Saxenda bags FDA approval for weight management
This article was originally published in Scrip
Executive Summary
With US FDA approval for Saxenda (liraglutide) Novo Nordisk could be a contender in the market for prescription weight loss drugs, which so far has yielded disappointing sales from oral obesity therapies approved in the US since 2012 starting with Belviq (lorcaserin) from Arena Pharmaceuticals.
You may also be interested in...
Novo’s H1 Exceeds Estimates On GLP-1, Obesity Sales Performance
The company’s semaglutide franchise pushed net sales for the first half of 2021 up 5% year over year at DKK66.8bn ($10.6bn), helped by double- and triple-digit growth for Ozempic and Rybelsus.
Novo Nordisk Hopes To Gradually Build US Access To Obesity Therapy
With US FDA approval of Wegovy for obesity, Novo Nordisk prices the weekly injectable at par with its other obesity brand Saxenda. Ramping up sales will require patient, clinician and payer education, the company says.
Eisai's Obesity Drug Belviq Passes Cardiovascular Outcomes Test
The Japanese pharma says it will discuss the data with US FDA, with hopes of potential to incorporate secondary endpoint data in labeling.